FDA delays action date for Raptor's cystinosis drug Procysbi

12/30/2012 | American City Business Journals

The FDA postponed from Jan. 30 to April 30 its expected decision on Raptor Pharmaceutical's cystinosis drug Procysbi, a delayed-release version of cysteamine. The agency did not ask for more studies. The FDA is expected to approve Procysbi, but it has yet to decide on orphan-drug exclusivity, an analyst said.

View Full Article in:

American City Business Journals

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Fort Worth, TX
Director, Senior Legal Counsel
Fort Worth, TX
Corporate Counsel - Healthcare Law Group
South San Francisco, CA
Manager/Senior Manager, Health Services Analytics
Avalere Health
Washington, DC